MAIA Biotechnology Completes International Enrollment in Phase 2 Lung Cancer Trial — MAIA Biotechnology, Inc.

Event summary

MAIA Biotechnology completed international enrollment in Part C of its Phase 2 THIO-101 trial for third-line non-small cell lung cancer (NSCLC).
41 patients were enrolled across Taiwan, Turkey, Poland, Hungary, Romania, and Georgia.
Domestic enrollment is underway at three U.S. clinical sites.
Ateganosine, the lead candidate, showed median survival of 17.8 months in earlier trial parts.

The big picture

MAIA Biotechnology's completion of international enrollment in its Phase 2 trial marks a critical step in validating ateganosine as a potential third-line treatment for NSCLC. The trial's design, combining telomere-targeting with immune activation, addresses a significant unmet need in heavily pre-treated patients. With FDA Fast Track designation already secured, the company is positioning itself for accelerated regulatory review, potentially shortening the path to market if efficacy data holds.

What we're watching

Regulatory Advantage: Whether FDA's Fast Track designation will expedite ateganosine's approval process.
Clinical Efficacy: The pace at which mature data from Part C confirms or contradicts earlier survival metrics.
Market Differentiation: How ateganosine's dual-mechanism approach positions it against existing NSCLC therapies.